OAM
CUE icon

Oxford Asset Management’s Cue Biopharma CUE Stock Holding History

Oxford Asset Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-603
Closed -$287K – 478
2019
Q4 		$287K Sell
603
-284
-32% -$89.2K 0.01% 1452
2019
Q3 		$224K Buy
+887
New +$213K 0.01% 1546
2019
Q1 		– Sell
-648
Closed -$91K – 1714
2018
Q4 		$91K Buy
+648
New +$118K ﹤0.01% 1659

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Oxford Asset Management's CUE Position: Q1 2020 in Review

Oxford Asset Management sold out of Cue Biopharma (CUE) in Q1 2020, closing a stake of 603 shares — an estimated $287K sold.

Oxford Asset Management first reported a position in CUE in Q4 2018 and held it in 3 quarters. The position peaked at $287K in Q4 2019. 74 funds tracked by Wall St. Rank hold CUE as of Q1 2020.

  • Oxford Asset Management reported no remaining Cue Biopharma position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 603 Cue Biopharma shares in Q1 2020, an estimated $287K.
  • Oxford Asset Management first reported a position in Cue Biopharma in Q4 2018 and held it in 3 quarters.
  • Oxford Asset Management's Cue Biopharma position peaked at $287K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.